Literature DB >> 19737618

Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007.

Adam K Cheknis1, Susan P Sambol, David M Davidson, Kristin J Nagaro, Maria C Mancini, G Aida Hidalgo-Arroyo, Jon S Brazier, Stuart Johnson, Dale N Gerding.   

Abstract

Clostridium difficile is a widely distributed pathogen with multiple strain types as determined by restriction endonuclease analysis (REA) and by PCR ribotyping, two well-characterized typing systems. In this study, REA typing was performed on 894C. difficile isolates from patients enrolled from 16 countries on three continents in two large, recently conducted clinical treatment trials of C. difficile infection. REA group BI (Ribotype 027) isolates were the most common strains identified and were widely distributed throughout North America, but restricted to three of thirteen countries in Europe. REA group J (Ribotype 001) isolates were the most common strains identified in Europe and non-specific REA groups (historically less frequent) were the most common strains identified in Australia. REA groups BI, J, G and CF correlated with specific PCR ribotypes whereas more than one ribotype was found within REA groups Y, BK, and K. International surveillance of C. difficile strains is important to document the changing epidemiology of this enteric pathogen that continues to cause healthcare facility outbreaks and sporadic infections in other settings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737618     DOI: 10.1016/j.anaerobe.2009.09.001

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  28 in total

1.  Prevalence and risk factors for asymptomatic Clostridium difficile carriage.

Authors:  Faisal Alasmari; Sondra M Seiler; Tiffany Hink; Carey-Ann D Burnham; Erik R Dubberke
Journal:  Clin Infect Dis       Date:  2014-04-21       Impact factor: 9.079

2.  Clostridium difficile ribotype diversity at six health care institutions in the United States.

Authors:  Sheila Waslawski; Eugene S Lo; Sarah A Ewing; Vincent B Young; David M Aronoff; Susan E Sharp; Susan M Novak-Weekley; Arthur E Crist; W Michael Dunne; Joan Hoppe-Bauer; Michelle Johnson; Stephen M Brecher; Duane W Newton; Seth T Walk
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

3.  Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

Authors:  Andre J Marozsan; Dangshe Ma; Kirsten A Nagashima; Brian J Kennedy; Yun Kenneth Kang; Robert R Arrigale; Gerald P Donovan; Wells W Magargal; Paul J Maddon; William C Olson
Journal:  J Infect Dis       Date:  2012-06-25       Impact factor: 5.226

4.  Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013.

Authors:  Isabella A Tickler; Richard V Goering; Joseph D Whitmore; Ashley N W Lynn; David H Persing; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

5.  Evolutionary dynamics of Clostridium difficile over short and long time scales.

Authors:  Miao He; Mohammed Sebaihia; Trevor D Lawley; Richard A Stabler; Lisa F Dawson; Melissa J Martin; Kathryn E Holt; Helena M B Seth-Smith; Michael A Quail; Richard Rance; Karen Brooks; Carol Churcher; David Harris; Stephen D Bentley; Christine Burrows; Louise Clark; Craig Corton; Vicky Murray; Graham Rose; Scott Thurston; Andries van Tonder; Danielle Walker; Brendan W Wren; Gordon Dougan; Julian Parkhill
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

6.  A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.

Authors:  Natalie G Anosova; Leah E Cole; Lu Li; Jinrong Zhang; Anna M Brown; Sophia Mundle; Jianxin Zhang; Satyajit Ray; Fuqin Ma; Pierre Garrone; Nicola Bertraminelli; Harry Kleanthous; Stephen F Anderson
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

7.  Clostridium difficile ribotype does not predict severe infection.

Authors:  Seth T Walk; Dejan Micic; Ruchika Jain; Eugene S Lo; Itishree Trivedi; Eugene W Liu; Luay M Almassalha; Sarah A Ewing; Cathrin Ring; Andrzej T Galecki; Mary A M Rogers; Laraine Washer; Duane W Newton; Preeti N Malani; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2012-09-12       Impact factor: 9.079

8.  Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.

Authors:  Casey M Theriot; Charles C Koumpouras; Paul E Carlson; Ingrid I Bergin; David M Aronoff; Vincent B Young
Journal:  Gut Microbes       Date:  2011-11-01

Review 9.  Clostridium difficile Infection.

Authors:  Jae Hyun Shin; Esteban Chaves-Olarte; Cirle A Warren
Journal:  Microbiol Spectr       Date:  2016-06

10.  U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.

Authors:  D R Snydman; L A McDermott; N V Jacobus; C Thorpe; S Stone; S G Jenkins; E J C Goldstein; R Patel; B A Forbes; S Mirrett; S Johnson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.